- Home
- SNAL vs PLUR Comparison
SNAL vs PLUR Comparison
Compare SNAL & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNAL | PLUR |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8M | 33.9M |
| IPO Year | 2022 | 2001 |
Fundamental Metrics
Financial Performance| Metric | SNAL | PLUR |
|---|---|---|
| Price | $0.64 | $3.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 19.7K | 5.5K |
| Earning Date | 03-19-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $84,467,047.00 | $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | $50.41 | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 38.69 | ★ 309.82 |
| 52 Week Low | $0.56 | $2.82 |
| 52 Week High | $2.15 | $7.13 |
Technical Indicators
Market Signals| Indicator | SNAL | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 38.84 |
| Support Level | $0.58 | $2.91 |
| Resistance Level | $0.71 | $3.42 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 28.31 | 5.00 |
Price Performance
Historical ComparisonAbout SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.